Heart transplantation is an accepted treatment for select patients with end-stage heart
failure. Improvements to immunosuppressive therapies and patient management have …

Heart transplantation (HT) is an established life-saving treatment option for patients with end-
stage heart failure. Despite many advances in the field, the development of acute cellular …

Effective antirejection therapy and infection control have significantly improved the long-term
survival of heart transplant recipients, but coronary allograft vasculopathy remains an …

Cardiac allograft vasculopathy (CAV) is an obliterative and diffuse form of vasculopathy
affecting almost 50% of patients after 10 years from heart transplant and represents the most …

Cardiac allograft vasculopathy (CAV) is the leading cause of long-term graft dysfunction in
patients with heart transplantation and is linked with significant morbidity and mortality …

Success in cardiac transplantation has been achieved by the development of improved
immunosuppressive therapies, which have led to a concomitant decrease in cardiac …

Since the first human heart transplantation was performed in 1967, the field of heart
transplantation has advanced to the point where survival and acceptable quality of life are …

Despite the widespread use of echocardiography in the cardiac allograft recipient, the
clinical usefulness of this practice is not well defined. In this article, the authors review the …

Cardiac allograft vasculopathy (CAV) is an important cause of morbidity and mortality among
cardiac transplant recipients. CAV occurs in approximately 30% of patients by 5 years and …

Cardiac allograft vasculopathy (CAV) is common, with a prevalence of 52% at 10 years after
transplantation, and represents a leading cause of death beyond the first year, responsible …